## Sascha Pahernik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10904341/publications.pdf

Version: 2024-02-01

95 papers

3,620 citations

28 h-index 57 g-index

95 all docs 95 docs citations

95 times ranked 4847 citing authors

#	Article	IF	CITATIONS
1	A Forgotten Ureteral Stent: Potential Risks for the Urinary Function. Urologia Internationalis, 2022, 106, 209-212.	0.6	1
2	Neural Networks Modeling for Prediction of Required Resources for Personalized Endourologic Treatment of Urolithiasis. Journal of Personalized Medicine, 2022, 12, 784.	1.1	2
3	Magnetic resonance imagingâ€guided transurethral ultrasound ablation in patients with localised prostate cancer: 3â€year outcomes of a prospective Phase I study. BJU International, 2021, 127, 544-552.	1.3	13
4	Combination of Robotic Pyeloplasty and Percutaneous Renal Surgery for Simultaneous Treatment of Ureteropelvic Junction Obstruction and Calyx Stones. Urologia Internationalis, 2021, 105, 637-641.	0.6	8
5	Single-Center Evaluation of Treatment Success Using Two Different Protocols for MRI–Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer. Frontiers in Oncology, 2021, 11, 782546.	1.3	O
6	External validation of novel magnetic resonance imagingâ€based models for prostate cancer prediction. BJU International, 2020, 125, 407-416.	1.3	20
7	Modulating the Heat Sensitivity of Prostate Cancer Cell Lines In Vitro: A New Impact for Focal Therapies. Biomedicines, 2020, 8, 585.	1.4	2
8	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1983-1992.	0.5	18
9	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget, 2019, 10, 17-29.	0.8	21
10	Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. Future Science OA, 2018, 4, FSO299.	0.9	3
11	Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound. Journal of Urology, 2018, 199, 983-989.	0.2	67
12	Complete bladder neck preservation promotes long-term post-prostatectomy continence without compromising midterm oncological outcome: analysis of a randomised controlled cohort. World Journal of Urology, 2018, 36, 349-355.	1.2	23
13	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e11-79.e17.	0.8	14
14	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	1.6	27
15	Response to Bieko re: Risk of Radiation-Induced Cataracts: Investigation of Radiation Exposure to the Eye Lens During Endourological Procedures. Journal of Endourology, 2018, 32, 905-906.	1.1	1
16	Genomic features of renal cell carcinoma with venous tumor thrombus. Scientific Reports, 2018, 8, 7477.	1.6	19
17	Risk of Radiation-Induced Cataracts: Investigation of Radiation Exposure to the Eye Lens During Endourologic Procedures. Journal of Endourology, 2018, 32, 897-903.	1.1	13
18	Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. Oncotarget, 2018, 9, 22537-22545.	0.8	4

#	Article	IF	CITATIONS
19	Ureterocystoneostomy in complex oncological cases with an "Uebelhoer―modified Boari bladder flap. Langenbeck's Archives of Surgery, 2017, 402, 1271-1278.	0.8	6
20	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) Tj ETQq0 0 0 rgBT	√ <b>©</b> øerlock	₹40 Tf 50 6
21	The Value of PSA Density in Combination with PI-RADSâ,,¢ for the Accuracy of Prostate Cancer Prediction. Journal of Urology, 2017, 198, 575-582.	0.2	179
22	Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. Langenbeck's Archives of Surgery, 2017, 402, 637-644.	0.8	22
23	Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer. Progress in Transplantation, 2017, 27, 365-368.	0.4	O
24	Risk factors of long-term postoperative renal function after partial nephrectomy in a solitary kidney. Open Life Sciences, 2017, 12, 481-488.	0.6	3
25	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. Journal of Cancer, 2017, 8, 507-512.	1.2	2
26	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	0.8	14
27	MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget, 2017, 8, 1046-1057.	0.8	26
28	Prognostic relevance of androgen receptor expression in renal cell carcinomas. Oncotarget, 2017, 8, 78545-78555.	0.8	15
29	Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 238.e9-238.e17.	0.8	7
30	Risk factors for long-term outcome in photoselective vaporization of the prostate. Scandinavian Journal of Urology, 2016, 50, 313-318.	0.6	1
31	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. Journal of Surgical Oncology, 2016, 114, 764-768.	0.8	26
32	Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. Journal of Neuro-Oncology, 2016, 130, 221-228.	1.4	26
33	Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nature Communications, 2016, 7, ncomms11845.	5.8	44
34	Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 433.e1-433.e8.	0.8	21
35	Magnetic Resonance Imaging–Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. European Urology, 2016, 70, 447-455.	0.9	73
36	Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. Clinical Genitourinary Cancer, 2016, 14, e379-e385.	0.9	13

#	Article	IF	CITATIONS
37	A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. European Urology, 2016, 69, 94-102.	0.9	201
38	The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. Oncotarget, 2016, 7, 418-432.	0.8	28
39	Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications. Translational Oncology, 2015, 8, 480-486.	1.7	4
40	<scp>PBRM1</scp> ( <scp>BAF180</scp> ) protein is functionally regulated by p53â€induced protein degradation in renal cell carcinomas. Journal of Pathology, 2015, 237, 460-471.	2.1	18
41	Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin. Stem Cell Reports, 2015, 4, 503-518.	2.3	24
42	Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney International, 2015, 87, 74-84.	2.6	327
43	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology, 2015, 193, 436-442.	0.2	27
44	SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology, 2015, 68, 837-847.	0.9	116
45	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. Clinical Genitourinary Cancer, 2015, 13, e145-e152.	0.9	16
46	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. Journal of Urology, 2015, 194, 304-309.	0.2	28
47	Interdisciplinary counseling service for renal malignancies: A patient-centered approach to raise guideline adherence. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 23.e1-23.e7.	0.8	11
48	A European Multicenter Randomized Noninferiority Trial Comparing 180 W GreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. Journal of Urology, 2015, 193, 570-578.	0.2	117
49	Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World Journal of Urology, 2015, 33, 833-839.	1.2	5
50	Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma. Neoplasia, 2014, 16, 1028-1035.	2.3	15
51	180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trialâ $\in$ "The GOLIATH Study. European Urology, 2014, 65, 931-942.	0.9	189
52	Preoperative decision making for renal cell carcinoma: Cystic morphology in cross-sectional imaging might predict lower malignant potential. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 37.e1-37.e6.	0.8	21
53	Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma1Present address:  Department of Urology, University Hospital Frankfurt, Germany.2Equal contributions Urologic Oncology: Seminars and Original Investigations, 2014, 32, 877-884.	0.8	11
54	The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World Journal of Urology, 2014, 32, 1537-1542.	1.2	13

#	Article	IF	CITATIONS
55	Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Current Urology Reports, 2014, 15, 404.	1.0	60
56	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. European Urology, 2014, 66, 577-583.	0.9	76
57	Pitfalls of electromagnetic tracking in clinical routine using multiple or adjacent sensors. International Journal of Medical Robotics and Computer Assisted Surgery, 2013, 9, 268-273.	1.2	10
58	Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). European Urology, 2013, 64, 472-477.	0.9	91
59	Multimedia Support for Improving Preoperative Patient Education: A Randomized Controlled Trial Using the Example of Radical Prostatectomy. Annals of Surgical Oncology, 2013, 20, 15-23.	0.7	64
60	Impact of Complete Bladder Neck Preservation on Urinary Continence, Quality of Life and Surgical Margins After Radical Prostatectomy: A Randomized, Controlled, Single Blind Trial. Journal of Urology, 2013, 189, 891-898.	0.2	82
61	Impact of Clinical and Histopathological Parameters on Disease Specific Survival in Patients with Collecting Duct Renal Cell Carcinoma: Development of a Disease Specific Risk Model. Journal of Urology, 2013, 190, 458-463.	0.2	31
62	Pediatric Case Report on Magnetic Resonance Imaging/Transrectal Ultrasound-fusion Biopsy of Rhabdomyosarcoma of the Bladder/Prostate: A New Tool To Reduce Therapy-associated Morbidity?. Urology, 2013, 81, 417-420.	0.5	6
63	Two decades' experience with a prospective biobank for urologic oncology: research, clinical care, and the patients' view. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 990-996.	0.8	28
64	Time to recurrence is a significant predictor of cancerâ€specific survival after recurrence in patients with recurrent renal cell carcinoma – results from a comprehensive multiâ€centre database ( <scp>CORONA</scp> / <scp>SATURN</scp> â€ <scp>P</scp> roject). BJU International, 2013, 112, 909-916.	1.3	69
65	Intraoperative electron radiation therapy (IOERT) in patients with locally recurrent renal cell carcinoma. Radiation Oncology, 2013, 8, 282.	1.2	11
66	Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study) Journal of Clinical Oncology, 2013, 31, TPS4591-TPS4591.	0.8	4
67	Phantom Study of a Novel Stereotactic Prostate Biopsy System Integrating Preinterventional Magnetic Resonance Imaging and Live Ultrasonography Fusion. Journal of Endourology, 2012, 26, 807-813.	1.1	22
68	Urinary Diversion. Deutsches Ärzteblatt International, 2012, 109, 617-22.	0.6	27
69	Patients' View of Their Preoperative Education for Radical Prostatectomy: Does It Change After Surgery?. Journal of Cancer Education, 2012, 27, 377-382.	0.6	10
70	Multimedia support in preoperative patient education for radical prostatectomy: The physicians' point of view. Patient Education and Counseling, 2012, 87, 239-242.	1.0	25
71	PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy. World Journal of Urology, 2012, 30, 91-95.	1.2	4
72	Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response. Urologia Internationalis, 2011, 86, 256-260.	0.6	8

#	Article	IF	CITATIONS
73	Selective Transarterial Embolization for Posttraumatic Renal Hemorrhage: A Second Try is Worthwhile. Journal of Urology, 2011, 185, 1751-1755.	0.2	40
74	A Novel Stereotactic Prostate Biopsy System Integrating Pre-Interventional Magnetic Resonance Imaging and Live Ultrasound Fusion. Journal of Urology, 2011, 186, 2214-2220.	0.2	165
<b>7</b> 5	Decisionâ€making in localized prostate cancer: lessons learned from an online support group. BJU International, 2011, 107, 1570-1575.	1.3	41
76	Navigated renal access using electromagnetic tracking: an initial experience. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 1307-1312.	1.3	35
77	Preoperative Hydronephrosis Predicts Advanced Bladder Cancer but Is Not an Independent Factor for Cancer-Specific Survival after Radical Cystectomy. Urologia Internationalis, 2011, 86, 25-30.	0.6	13
78	Renal cell cancer-a multimodal approach to preserving renal function and improving survival. Nephrology Dialysis Transplantation, 2011, 26, 3086-3088.	0.4	1
79	Small renal cell carcinoma: oncological outcome with tumour size. Scandinavian Journal of Urology and Nephrology, 2011, 45, 432-435.	1.4	5
80	Prognostic Factors Influencing Long-Term Survival of Patients Undergoing Nephron-Sparing Surgery for Nonmetastatic Renal-Cell Carcinoma (RCC) with Imperative Indications. Annals of Surgical Oncology, 2010, 17, 544-551.	0.7	11
81	Risk factors and clinical management of haemorrhage after open nephronâ€sparing surgery. BJU International, 2010, 106, 1488-1493.	1.3	13
82	Positive surgical margins after partial nephrectomy. Nature Reviews Urology, 2010, 7, 240-242.	1.9	0
83	Survival in prostate cancer patientsÂ≥70Âyears after radical prostatectomy and comparison to younger patients. World Journal of Urology, 2009, 27, 637-642.	1.2	17
84	Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a midâ€European study population?. BJU International, 2009, 103, 877-882.	1.3	21
85	Vaporization of prostates of ≥80 mL using a potassiumâ€ŧitanylâ€phosphate laser: midtermâ€ŧesults and comparison with prostates of <80 mL. BJU International, 2008, 102, 322-327.	1.3	95
86	Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?. BJU International, 2008, 102, 1413-1418.	1.3	119
87	Elective Nephron Sparing Surgery for Renal Cell Carcinoma Larger Than 4 cm. Journal of Urology, 2008, 179, 71-74.	0.2	87
88	Prognostic Stratification of Localized Renal Cell Carcinoma by Tumor Size. Journal of Urology, 2008, 180, 62-67.	0.2	34
89	Small Renal Tumors: Correlation of Clinical and Pathological Features With Tumor Size. Journal of Urology, 2007, 178, 414-417.	0.2	140
90	Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU International, 2007, 100, 26-29.	1.3	39

#	Article	IF	CITATIONS
91	Nephron sparing surgery for renal cell carcinoma in a solitary kidney. World Journal of Urology, 2007, 25, 513-517.	1.2	25
92	Rectosigmoid Pouch (Mainz Pouch II) in Children. Journal of Urology, 2006, 175, 284-287.	0.2	51
93	Nephron Sparing Surgery for Renal Cell Carcinoma With Normal Contralateral Kidney: 25 Years of Experience. Journal of Urology, 2006, 175, 2027-2031.	0.2	107
94	Conversion from colonic conduit into recto-sigmoid pouch (Mainz pouch II). BJU International, 2006, 97, 157-160.	1.3	4
95	CONVERSION FROM COLONIC OR ILEAL CONDUIT TO CONTINENT CUTANEOUS URINARY DIVERSION. Journal of Urology, 2004, 171, 2293-2297.	0.2	20